MedPath

SHENYAN SANSHAIN FARMASYUTIKAL KO., LTD., PREDSTAVITELSTVO

🇷🇺Russia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

31

Active:0
Completed:5

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:16
Phase 2:5
+3 more phases

Drug Approvals

9

PHILIPPINES:9

Drug Approvals

None

Approval Date
Jul 14, 2025
PHILIPPINES

Aropotin

Approval Date
Jul 14, 2025
PHILIPPINES

Gotein

Approval Date
Jul 14, 2025
PHILIPPINES

Epolitt

Approval Date
Jul 14, 2025
PHILIPPINES

Aepotin

Approval Date
Jul 14, 2025
PHILIPPINES

Eprohab

Approval Date
Jul 14, 2025
PHILIPPINES

Epiao

Approval Date
Jul 14, 2025
PHILIPPINES

Epson 4000IU

Approval Date
Jul 14, 2025
PHILIPPINES

Eporife

Approval Date
Jul 14, 2025
PHILIPPINES

Clinical Trials

Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials

Phase 1
16 (53.3%)
Phase 2
5 (16.7%)
Phase 3
4 (13.3%)
Not Applicable
2 (6.7%)
Phase 4
2 (6.7%)
Early Phase 1
1 (3.3%)

Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects

Not Applicable
Not yet recruiting
Conditions
Safety Issues
Interventions
Drug: SSS55
First Posted Date
2025-07-10
Last Posted Date
2025-07-10
Lead Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Target Recruit Count
26
Registration Number
NCT07058779

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects

Not Applicable
Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
First Posted Date
2025-07-10
Last Posted Date
2025-07-10
Lead Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Target Recruit Count
48
Registration Number
NCT07057726
Locations
🇨🇳

SSS39, Beijing, China

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

Phase 1
Not yet recruiting
Conditions
Advanced Malignant Tumors
Interventions
Drug: SPGL008
First Posted Date
2025-06-26
Last Posted Date
2025-06-26
Lead Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Target Recruit Count
96
Registration Number
NCT07038005

A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Malignant Tumors
Interventions
First Posted Date
2025-06-23
Last Posted Date
2025-07-25
Lead Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Target Recruit Count
30
Registration Number
NCT07032298
Locations
🇨🇳

The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, China

A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese Males

Phase 1
Not yet recruiting
Conditions
Healthy Subjects (HS)
Interventions
Drug: [14C]SSS17
First Posted Date
2025-06-18
Last Posted Date
2025-06-25
Lead Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Target Recruit Count
6
Registration Number
NCT07025915
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.